Objective: Repetitive transcranial magnetic stimulation (rTMS) applied to the dorsolateral prefrontal cortex (DLPFC) has yielded promising results as a treatment for posttraumatic stress disorder (PTSD). However, to date, no quantitative review of its clinical utility has been published.
Limitations
• The generalizability of our findings is somewhat limited by the small number of subjects included in the analyses, the heterogeneity of the stimulation protocols, and the lack of medium-to long-term effectiveness data on rTMS for PTSD.
A severe and often chronic psychiatric illness with a lifetime prevalence in community samples of up to 8%, 1,2 PTSD occurs in susceptible people who have been exposed to extremely traumatic events that involved actual or threatened death or serious injury, or a threat to the physical integrity of self or others. 3 PTSD is characterized by pervasive hyperarousal, intrusive thoughts, exaggerated startle response, flashbacks, nightmares, sleep disturbances, emotional numbness, and persistent avoidance of traumaassociated stimuli, 4 and is associated with significant personal distress and disability, as well as with high social and economic costs. 5, 6 Current first-line treatment strategies for PTSD include ADs (for example, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors) and psychotherapy (for example, prolonged exposure or trauma-focused cognitive-behavioral therapy). 7, 8 However, a considerable proportion of patients with PTSD remain significantly ill despite undergoing such relatively diverse therapeutic options, and are thereby left with lasting negative repercussions on their global functioning and well-being. 9 Therefore, novel treatments for PTSD are of considerable interest, one of which is rTMS. 10 rTMS is a noninvasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil of wire placed over the scalp. 11 Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies of 1 Hz or less (LF-rTMS) usually being inhibitory and higher frequencies (≥5 Hz; HF-rTMS) usually being excitatory. 12 To date, rTMS has been shown, for example, to be an effective treatment for MDD and schizophrenia. 13, 14 Although the pathophysiology of PTSD remains unclear, growing evidence from functional neuroimaging studies suggest that it is consistently associated with hypoactivation of the prefrontal cortex (including medial and dorsolateral regions) and hyperactivation of deeper brain structures, such as the amygdala. [15] [16] [17] The DLPFC, in particular, is involved in many complex cognitive and behavioural functions that are relevant to PTSD 18, 19 and that have been shown to be reliably modulated by rTMS (for example, executive functioning, 20, 21 working memory, 22,23 verbal memory, 24 supervisory attentional control, 25, 26 and reasoning and decision making 27, 28 ). As a result, numerous recent open-label trials and RCTs have been carried out and have shown that rTMS targeting the DLPFC is potentially useful for treating PTSD. [29] [30] [31] [32] [33] [34] However, to date, no attempt has been made to integrate the findings from these studies to produce a more accurate estimation of the efficacy and acceptability of rTMS applied to the right and the left DLPFC for PTSD. Therefore, we conducted the present systematic review and exploratory meta-analysis to examine this issue.
Methodology of the Literature Review

Search Strategy
We identified articles for inclusion in this meta-analysis by searching MEDLINE, Embase, PsycINFO, CENTRAL, and SCOPUS from January 1, 1995, to March 12, 2013, and (g de Hedges = 1,24; P = 0,02) et dépressifs (g de Hedges = 0,85; P < 0,001). Les taux d'abandon au terme de l'étude ne différaient pas entre les groupes de SMTr active et de SMTr simulée. En ce qui concerne la SMTr appliquée au CDLPF gauche, il n'y a qu'une étude publiée à ce jour (utilisant un protocole de haute fréquence), et les résultats indiquent que la SMTr active semble être généralement supérieure à la SMTr simulée. by screening the bibliography of all included studies. The search syntaxes included a combination of the following key words: "transcranial magnetic," "rTMS," "magnetic stimulation," "stress*," "PTSD," and "trauma*." Detailed information regarding the search procedures (including syntaxes, parameters, and results) are shown in the online eAppendix.
Conclusions
Study Selection
Candidate studies (judged by their title and abstract) had to satisfy the following criteria 35 : study validity-random allocation, double-blinded, sham-controlled (that is, coil angled on the scalp or use of a sham coil), parallel design, of 5 subjects or more with PTSD randomized per study arm; sample characteristics-subjects aged 18 to 75 years with a diagnosis of primary PTSD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 36 or the International Classification of Diseases, Tenth Revision 
Data Extraction
Data were recorded in a structured fashion as follows: sample characteristics-mean age, sex, and illness severity; rTMS-related-stimulation frequency and intensity (including the total number of stimuli delivered), number of treatment sessions, and type of sham; primary outcome measure-score changes (pre-and post-rTMS) on validated clinician-reported measures (for example, the TreatmentOutcome PTSD Scale 38 ); secondary outcome measurescore changes (pre-and post-rTMS) on validated selfreported measures (for example, the PTSD Checklist
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); tertiary outcome measures-score changes (pre-and postrTMS) on validated anxiety (for example, the Hamilton Anxiety Rating Scale 40 and the State-Trait Anxiety Inventory 41 ), and depression (for example, the Hamilton Depression Rating Scale 42 and the Beck Depression Inventory 43 ) measures; and, acceptability of treatmentoverall dropout rates for active and sham rTMS groups at study end.
Study Quality
We used the well-known Jadad Scale to assess the quality of the included RCTs. 44 Criteria evaluated by this scale include randomization, blinding, and report of participant withdrawal, and possible scores range from 0 to 5. A priori, studies with a Jadad score of 3 or more were deemed higher quality and those with a score of 0 to 2 were classified as lower quality. 45 
Data Synthesis and Analyses
Analyses were performed using Comprehensive MetaAnalyses version 2.0 (Biostat, Englewood, NJ) and IBM SPSS version 20 (IBM Corporation, Chicago, IL).
We used a random-effects model as we assumed that the true ESs had likely varied between the included RCTs.
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If provided, intention-to-treat data, using a method, such as LOCF, were preferred over data from completers. 47 Score changes (pre-and post-rTMS) were investigated with pooled Hedges g ESs. As we could not retrieve the correlations between pre-and post-rTMS measures from the individual RCTs, we followed the recommendation by Rosenthal 48 and assumed a conservative estimation (r = 0.7). Also, as recommended by the Cochrane Collaboration, 35 in studies comparing 3 treatment conditions (that is, 2 active, compared with 1 sham), we split the control group into 2 equal parts (so that the total number of control subjects added up to its original size) and compared each half with the 2 active conditions. For the study by Boggio et al, 31 we had to estimate the means and standard deviations by, respectively, reviewing the published graphs and imputting average values from other RCTs included in this metaanalysis. 49 Acceptability of treatment was assessed with odds ratios for differential dropout rates between active and sham rTMS groups. 50, 51 Also, to rule out the presence of baseline between-group differences in illness severity, we computed pooled Hedges g ESs for subjects' PTSD, depression, and anxiety scores. Finally, we carried out an exploratory analysis by subgrouping the included studies into LF-and HF-rTMS protocols.
Heterogeneity was assessed using the Q statistic and I 2 index. 52 Values of P < 0.1 for the former and (or) more than 35% for the latter were deemed as indicative of significant between-study heterogeneity. 50 We further used funnel plots, the fail-safe number (that is, the number of missing studies that would make a specific result statistically nonsignificant at P > 0.05), 53 and Egger's Regression Intercept 54 to test for the presence of publication bias. 50, 52 Pooled statistical analyses were not conducted when 2 studies or less were available for a particular brain target (that is, left or right DLPFC) owing to the impossibility of producing funnel plots and estimating publication bias. 55 Instead, in this context we reported individual study results in a descriptive manner only.
Results
Literature Search
We retrieved 98 references (after discarding duplicates) from MEDLINE, PsycINFO, Embase, CENTRAL, and SCOPUS. Among these, 3 met the eligibility criteria, [31] [32] [33] comprising 4 comparisons between active and sham rTMS applied to the right DLPFC and a single comparison between active and sham rTMS applied to the left DLPFC.
Study Quality and Strategy for Missing Data
The 3 included RCTs had a score of 3 or more in the Jadad Scale and were thus considered to have a high overall methodological quality. Regarding the strategies used by the RCTs to deal with missing data, 1 employed the LOCF approach, 31 1 performed completers-only analyses, 32 and 1 reported no patient dropout at study end.
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Repetitive Transcranial Magnetic Stimulation Over the Right Dorsolateral Prefrontal Cortex
Included Randomized Controlled Trials: Main Characteristics Three RCTs on rTMS applied to the right DLPFC were included in this meta-analysis, comprising 64 subjects with PTSD, of whom 38 were randomized to active rTMS (mean age 44.3 years [SD 6.5]; 68.4% males), and 26 were randomized to sham rTMS (mean age 48.8 years [SD 7.9]; 61.5% males). All RCTs administered 10 rTMS sessions in total, and the mean number of magnetic pulses delivered was 6250 (SD 6652). 1 The main characteristics of the included RCTs are described in Table 1 . The funnel plots and the additional forest plots are shown in the online eAppendix.
Clinician-Reported Posttraumatic Stress Disorder Symptoms
The pooled Hedges g ES for changes from baseline to end point on clinician-reported PTSD symptoms was 1.65 (95% CI 1.08 to 2.23; z = 5.66, P < 0.001), indicating a significant and large-sized difference in outcome favouring active rTMS (Figure 1 ).
Heterogeneity between RCTs did not exceed that expected by chance (Q = 2.63, df = 3, P = 0.45; I 2 = 0), implying that the variance among the ESs was not greater than expected by sampling error. Finally, the associated funnel plot was reasonably symmetrical, the fail-safe N was 28 and Egger's regression intercept was -1.77 (t = 0.43, df = 2, 2-tailed P = 0.71), all suggesting a low risk of publication bias.
Self-Reported Posttraumatic Stress Disorder Symptoms
The pooled Hedges g ES for changes from baseline to end point on self-reported PTSD symptoms was 1.91 (95% CI 1.07 to 2.74; z = 4.48, P < 0.001), indicating a significant and large-sized difference in outcome favouring active rTMS ( Figure 2 ).
Heterogeneity between RCTs was significant (Q = 5.58, df = 3, P = 0.13, I 2 = 46.21%). Visual inspection of the forest plot suggested that this was caused by the Cohen et al 32 LF-rTMS protocol, and its removal from the analysis resulted in nonsignificant heterogeneity (Q = 0.49, df = 2, P = 0.78, I 2 = 0%), although the clinical results remained unaltered in terms of a statistically significant betweengroup difference (Hedges g = 2.33, 95% CI 1.63 to 3.02; z = 6.54, P < 0.001). Finally, the associated funnel plot was reasonably symmetrical, the fail-safe N was 36, and Egger's regression intercept was -5.46 (t = 0.63, df = 2, 2-tailed P = 0.59), all suggesting a low risk of publication bias.
Overall Anxiety Symptoms
The pooled Hedges g ES for changes from baseline to end point on anxiety symptoms was 1.24 (95% CI 0.21 to 2.27; z = 2.37, P = 0.02), indicating a significant and large-sized difference in outcome favouring active rTMS (Figure 3 ). Heterogeneity between RCTs was significant (Q = 9.83, df = 3, P = 0.02, I 2 = 69.49%). Visual inspection of the forest plot suggested that this heterogeneity resulted from RCTs clearly subdivided into 2 groups: 1 reporting relatively high pre and post changes in anxiety symptoms (that is, the HF-rTMS protocols of Cohen et al 32 and Boggio et al 31 ), and the other reporting relatively low pre and post changes in anxiety symptoms (that is, the LF-rTMS protocols of Cohen et al 32 and Watts et al 33 ). Finally, the associated funnel plot was reasonably symmetrical, the fail-safe N was 16, and Egger's regression intercept was 1.24 (t = 0.19, df = 2, 2-tailed P = 0.87), all suggesting a low risk of publication bias.
Depressive Symptoms
The pooled Hedges g ES for changes from baseline to end point on depressive symptoms was 0.85 (95% CI 0.34 to 1.36; z = 3.28, P = 0.001), indicating a significant and large-sized difference in outcome favouring active rTMS (Figure 4 ).
Heterogeneity between RCTs was not statistically significant (Q = 0.85, df = 3, P = 0.84, I 2 = 0%). Finally, the associated funnel plot was reasonably symmetrical, the fail-safe N was 8, and Egger's regression intercept was 1.84 (t = 1.6, df = 2, 2-tailed P = 0.25), all suggesting a low risk of publication bias.
Acceptability of Repetitive Transcranial Magnetic Stimulation Treatment
Overall, no differences on dropout rates at study end were observed between active and sham rTMS groups (10.52% Heterogeneity between RCTs was not statistically significant (Q = 1.26, df = 3, P = 0.74, I 2 = 0%). Finally, the associated funnel plot was reasonably symmetrical, and Egger's regression intercept was -0.52 (t = 0.26, df = 2, 2-tailed P = 0.82), all suggesting a low risk of publication bias.
Baseline Illness Severity
Subjects receiving active rTMS (compared with those receiving sham rTMS) had significantly higher baseline scores on clinician-reported PTSD symptoms (Hedges g = 0.74, z = 2.86, P = 0.004), self-reported PTSD symptoms (Hedges g = 0.75, z = 2.87, P = 0.004), and depressive symptoms (Hedges g = 0.59, z = 2.33, P = 0.02). However, they did not differ in their baseline overall anxiety symptoms (Hedges g = 0.34, z = 1.34, P = 0.18).
Subgroup Analyses: High Frequency, Compared With Low Frequency, Repetitive Transcranial Magnetic Stimulation Protocols
Because of the small number of included RCTs we did not perform between-group statistical analyses. HF-rTMS protocols resulted in significant and large-sized improvements in clinician-reported PTSD symptoms (Hedges g = 2.05, z = 4.71, P < 0.001), self-reported PTSD symptoms (Hedges g = 2.32, z = 5.07, P < 0.001), overall anxiety symptoms (Hedges g = 2.15, z = 4.6, P < 0.001), and depressive symptoms (Hedges g = 0.79, z = 2.17, P = 0.03). In contrast, LF-rTMS protocols yielded statistically significant improvements in clinician-reported PTSD symptoms (Hedges g = 1.33, z = 3.36, P = 0.001), selfreported PTSD symptoms (Hedges g = 2.34, z = 4.13, Repetitive Transcranial Magnetic Stimulation Over the Dorsolateral Prefrontal Cortex for Treating Posttraumatic Stress Disorder P < 0.001), and depressive symptoms (Hedges g = 0.91, z = 2.47, P = 0.001), although there was no significant change in overall anxiety symptoms (Hedges g = 0.55, z = 1.38, P = 0.17).
Repetitive Transcranial Magnetic Stimulation Over the Left Dorsolateral Prefrontal Cortex
Only the RCT by Boggio et al 31 has reported efficacy data on rTMS applied to the left DLPFC. Briefly, they have shown that an HF protocol administered over 10 sessions was associated with a Hedges g ES for pre and post changes in clinician-rated and self-reported PTSD symptoms of 0.97 (95% CI 0.08 to 1.86; P = 0.03) and 1.29 (95% CI 0.36 to 2.22; P = 0.007), respectively. Further, they have reported a significant decrease in clinician-rated overall anxiety symptoms (Hedges g = 1.01; 95% CI 0.12 to 1.91, P = 0.03), but only a statistical trend toward a decrease in clinician-rated depressive symptoms (Hedges g = 0.86; 95% CI -0.02 to 1.75, P = 0.05).
Discussion
The main objective of our meta-analysis was to assess the efficacy and the acceptability of rTMS applied to the right and to the left DLPFC for treating PTSD. Briefly, we have shown that active rTMS applied to the right DLPFC significantly reduced clinician-rated and patientreported core PTSD symptoms, as well as overall anxiety and depressive symptoms following 10 daily sessions. Importantly, we found that patients who received active rTMS over the right DLPFC were significantly more ill at baseline, and it is possible that active treatment might have been even more effective than sham rTMS if both groups were comparable in terms of baseline psychopathology. Regarding rTMS applied over the left DLPFC, the only RCT published to date has shown promising results for an HF protocol although additional studies are needed to allow for pooled analyses. Finally, rTMS over the DLPFC seemed to be an acceptable treatment for PTSD as indexed by differential dropout rates at study end.
It is of interest that both LF-and HF-rTMS applied to the right DLPFC exerted a positive clinical effect on PTSD and its associated symptoms; this is counterintuitive, at least neurophysiologically, as LF-and HF-rTMS are believed to have opposite effects on cortical excitability (that is, usually inhibitory and excitatory effects, respectively). 56, 57 At present, there is no clear explanation for this paradoxical observation, although recent studies have shown, for example, that LF-rTMS at relatively low intensities (for example, ≤90% of the resting motor threshold) sometimes fails to induce a measurable change on motor excitability, and that its effects are associated with a large interindividual variability (perhaps related to the baseline excitability level of the targeted cortical area [58] [59] [60] ), with some subjects even showing facilitatory effects. 61 Nevertheless, our exploratory subgroup analyses further indicated that HF-rTMS protocols (compared with LF-rTMS protocols) may be associated with slightly greater clinical improvements in core PTSD symptoms (as assessed by clinician-rated measures), as well as in overall anxiety symptoms. This finding, although clearly preliminary, could be explained, at least in part, by the excitatory effects of HF-rTMS on the underlying cortical tissue that may have counteracted the hypofrontality usually observed in patients with PTSD and thus enhanced the modulation of fear-related emotional responses and encoding or consolidation of traumatic memories by indirectly inhibiting the amygdala. 15, 16, [62] [63] [64] Additionally, HF-rTMS might have inhibited contralateral brain structures involved in memory retrieval networks.
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In summary, the results of our meta-analysis only partially support the conventional model of the neurocircuitry underlying PTSD (involving relative hypoactivity of frontal regions and hyperactivity of subcortical regions, such as the amygdala 65 ), as we have shown that LF-rTMS (an inhibitory intervention) is also potentially effective for PTSD and might produce its therapeutic effects by inhibiting a possibly lateralized right-sided hyperactivity of the DLPFC. 31 However, one has to be extremely careful when attempting to explain the underlying neurobiology of PTSD and (or) the putative mechanisms of action of rTMS based on the results from these small RCTs.
Although clearly preliminary, our findings are encouraging when viewed in the context of more established treatments for PTSD. For example, a recent large meta-analysis has shown that ADs given for 4 to 12 weeks (compared with placebo) were associated with a Hedges g ES of 0.23 (95% CI 0.15 to 0.31; n = 4112) for reducing clinician-reported PTSD symptoms. 7 Further, prolonged exposure, a specific therapy that includes multiple sessions of imaginal and in vivo exposure, has been associated with a Hedges g ES of 1.08 (95% CI 0.69 to 1.46; n = 675) for improving core PTSD symptoms. 66 Also, a meta-analysis reported that the atypical APs risperidone and olanzapine, when used as add-ons or monotherapy (compared with placebo), were associated with a small-to-medium ES for reducing clinician-reported PTSD symptoms (that is, standardized mean difference = 0.45, 95% CI 0.14 to 0.75; n = 192).
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Nevertheless, as the optimum rTMS protocol for PTSD has yet to be determined, future studies should investigate the use of more intense treatment protocols (for example, higher numbers of total magnetic pulses and [or] percentage of the resting motor threshold), identify more clinically relevant neuromodulation protocols (for example, preconditioning paradigms or priming and different waveforms), 68, 69 as well as apply baseline electrophysiological and neuroimaging evaluations to better predict which patients will benefit from treatment. 70, 71 Also, further research should assess whether rTMS can potentiate the efficacy of a concomitantly administered psychotherapy. 10 Finally, novel developments in the field of neuromodulation, such as the H coil, 72 might also enhance the clinical utility of rTMS for PTSD by allowing the direct stimulation of relatively deeper brain structures, while theta burst stimulation might produce more consistent and enduring positive after-effects. 73 
Limitations
First, we only retrieved 3 RCTs with relatively small samples. Nevertheless, pooled analyses for rTMS applied to the right DLPFC already indicated significantly better clinical results for active, compared with sham, rTMS. Second, the quality of the available sham rTMS conditions is still unresolved, 12 and the use of coil tilting and (or) first-generation sham coils may not have been optimal. 74 In addition, we could not assess the integrity of blinding in the included RCTs owing to the absence of information in this regard. However, we have recently shown that a similar percentage of subjects with MDD receiving active, compared with sham, rTMS were able to correctly guess their treatment allocation at study end (that is, 52%, compared with 59%, respectively; risk difference = -0.04, z = -0.51, P = 0.61). 75 Third, the strategy most commonly used for locating the right DLPFC (that is, the 5 cm method) has been recently criticized for its inaccuracy 12 and future studies may benefit from the use of neuronavigation. 76 Fourth, we could not estimate the stability of the medium-to long-term effects of rTMS for PTSD or its cost-effectiveness, and this is especially relevant considering the labour-intensive and time-consuming nature of this treatment. 77 Nevertheless, preliminary evidence suggests that the positive clinical effects of rTMS for PTSD are sustained for up to 3 months following the study end. 31, 33 Fifth, the subgroup analyses should be seen as exploratory in nature and thus far from conclusive. Sixth, the reliability of the analyses of heterogeneity and publication bias might have been relatively low owing to the small number of included studies. 78 Seventh, the extensive use of imputation and the lack of an analysis of rTMS-related side effects are additional limitations of our study. Eight, our decision to pool the results of LF-and HF-rTMS protocols applied to the right DLPFC is also a potential limitation of our study, particularly considering their likely distinct neurophysiological basis. Finally, meta-analyses have often been criticized for the potential of publication bias and for the inclusion of poor-quality trials. 50 However, in our study these concerns were addressed by the comprehensive and systematic review of the literature and by the use of stringent inclusion criteria.
Conclusion
Our exploratory meta-analysis suggests that rTMS applied to the DLPFC is a promising new treatment for PTSD, even though its evidence base is still limited to a few clinical studies. Clearly, future larger-scale RCTs should first and foremost investigate the putative differential efficacy of HF-, compared with LF-, rTMS protocols, as well as of left, compared with right DLPFC coil placements. Additionally, they should explore whether patients with distinct subtypes of PTSD preferentially respond to rTMS, whether its beneficial effects are maintained over time, and whether the improvement in PTSD symptoms observed after rTMS treatment is mediated, for example, by changes in related psychopathological dimensions, such as depressive symptoms. Finally, considering its overall safety record 74, 79 and potential efficacy, we believe that rTMS could be currently offered, on a strictly humanitarian and compassionate basis, to patients with PTSD who remain significantly ill despite having received several conventional treatments for this condition (for example, pharmacotherapy and psychotherapy).
